CYCN.US Cyclerion Therapeutics Inc

Healthcare Biotechnology USA Stocks
3.36 USD
Close of Nov 14, 2026
1.03 36.33
Market cap
USD 2.25M
P/E
-
P/B
3.15x
ROE
-16.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CYCN.US undervalued?

Graham number

The Graham number of Cyclerion Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cyclerion Therapeutics Inc fundamental analysis

No fundamental analysis for Cyclerion Therapeutics Inc yet.

Cyclerion Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare ki…

Full company profile